Latest News and Press Releases

CHARLOTTE, N.C., July 3, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) received a written response from the U.S. Food and Drug Administration (FDA) to Chelsea's...

CHARLOTTE, N.C., June 21, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced results from an integrated dataset of two phase 3 studies, Study 301 and Study...

Officers and Directors Agree to 25% Reduction in Compensation Approximately 35% of Remaining Employees to Transition to Part-Time Status Chelsea Eliminating All Performance Bonuses Until...

CHARLOTTE, N.C., May 31, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that a preliminary analysis of its dose-ranging exploratory Phase II trial of...

Chelsea Proposing to Change Primary Endpoint and Submit Dizziness Data From Ongoing Study 306B to Support Resubmission of Northera NDA for the Treatment of Symptomatic Neurogenic Orthostatic...

In a press release issued earlier today by Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), please note the last sentence of the sixth paragraph should have read: Chelsea anticipates that...

Chelsea To Meet with FDA in May to Discuss Next Steps for Northera New Drug Application Postponing Conference Call Until Following FDA Meeting CHARLOTTE, N.C., May 1, 2012 (GLOBE...

CHARLOTTE, N.C., April 27, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that Horacio Kaufmann, M.D., Professor of Medicine, NYU Langone Medical...

CHARLOTTE, N.C., April 25, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today it is proud to serve as a platinum corporate sponsor of the Parkinson's Unity...

CHARLOTTE, N.C., April 20, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 19th Annual Future Leaders in the Biotech Industry Conference...